Join NovaBridge and its subsidiary, Visara, Inc. (Visara) for a Business Update Call featuring Nikolas JS London, MD, FACS (Managing Director, Retina Consultants San Diego), and Carlos Quezada-Ruiz, MD, FASRS (Chairman, Scientific Advisory Board, Visara), who will join NovaBridge and Visara management to discuss the Phase 2a trial evaluating VIS-101 for the treatment of wet age-related macular degeneration (wet AMD).

VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed to provide more rapid, robust and durable treatment benefits for patients with wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO).

NovaBridge Biosciences is a global biotechnology platform company committed to accelerating access to innovative medicines, and the majority shareholder of Visara. Visara is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH, and Chief Medical Officer, Cadmus Rich, MD, MBA.

A live question and answer session will follow the formal presentation.